Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA): Price and Financial Metrics
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Today's Latest Price: $11.96 USD
Updated Jan 15 7:00pm
Add TEVA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
TEVA Stock Summary
- TEVA has a market capitalization of $12,603,672,894 -- more than approximately 84.75% of US stocks.
- TEVA's went public 30.83 years ago, making it older than 84.17% of listed US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TEVA comes in at 15.87% -- higher than that of 88.28% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Teva Pharmaceutical Industries Ltd are OC, ATO, IMO, ASH, and VST.
- TEVA's SEC filings can be seen here. And to visit Teva Pharmaceutical Industries Ltd's official web site, go to www.tevapharm.com.
TEVA Stock Price Chart Interactive Chart >
TEVA Price/Volume Stats
| Current price | $11.96 | 52-week high | $13.76 |
| Prev. close | $11.50 | 52-week low | $6.25 |
| Day low | $11.50 | Volume | 12,430,400 |
| Day high | $12.06 | Avg. volume | 12,239,970 |
| 50-day MA | $10.08 | Dividend yield | N/A |
| 200-day MA | $10.53 | Market Cap | 13.06B |
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Company Bio
Teva Pharmaceuticals manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The company was founded in 1901 and is based in Petach Tikva, Israel.
TEVA Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $11.96 | $0.44 | -96% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Teva Pharmaceutical Industries Ltd. To summarize, we found that Teva Pharmaceutical Industries Ltd ranked in the 7th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Teva Pharmaceutical Industries Ltd ended up being:
- Interest coverage, a measure of earnings relative to interest payments, is -4.72 -- which is good for besting only 13.34% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- The company's compound free cash flow growth rate over the past 4.74 years comes in at -0.29%; that's greater than merely 5.5% of US stocks we're applying DCF forecasting to.
- 33% of the company's capital comes from equity, which is greater than just 9.87% of stocks in our cash flow based forecasting set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -96% |
| 1% | -96% |
| 2% | -96% |
| 3% | -96% |
| 4% | -96% |
| 5% | -96% |
NVST, SXTC, INFU, LUMO, and OSMT can be thought of as valuation peers to TEVA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...